Glioblastoma multiforme (GBM), a malignant astrocytic tumour, represents the most frequent tumour of the human brain. Nevertheless, its molecular pathology is not well understood. We utilized the immune system, which contributes to cancer protection, to help identify new GBM-related genes. By screening a human GBM cDNA library with autologous patient serum (SEREX-approach), we isolated a gene termed PHF3 (PHD finger protein 3). The gene product of PHF3 is immunogenic in GBM as tested in an allogenic patient serum screening demonstrating antibodies in 24 of 39 (61.53%) sera, whereas none of the 14 healthy persons had antibodies against PHF3. While previous SEREX studies revealed allogenic antibody responses up to 40%, our results for PHF3 represent the highest reported rate for a speci®c antibody response. We show that GBM patients with an antibody response against PHF3 show signi®cant better survival than patients without PHF3-speci®c antibodies. Because the amino acid sequence of PHF3 contains a PHD ®nger (also termed LAP motif), a TFIIS homology, a proline rich region and nuclear localization signals, it supposedly functions as a transcription factor. A polyclonal antibody generated against PHF3 shows nuclear expression in most investigated formalin-®xed, paran embedded tissues. In GBM, PHF3 expression is concentrated in cells surrounding necroses. Oncogene (2001) 20, 4107 ± 4114.
Introduction
Glioblastoma multiforme (GBM) represents the most malignant tumour of astrocytic origin, corresponding to WHO grade IV. The median survival time varies between 7 and 11 months (Daumas-Duport et al., 1988; Chinot and Martin, 1996) . The heterogeneous genetic pattern of glioma cells entails dysfunction of very dierent proteins or cellular regulation cycles (Biernat et al., 1997; Kleihues and Burger, 2000) . As known for several decades, the immune system is able to recognize tumour cells (Foley, 1953; Prehn and Main, 1957) . In recent years, the number of known tumour antigens has increased enormously. A variety of methods have been developed for identifying tumour antigens such as SEREX, cloning of T-cells and animal transplantation models (Old, 1981; Sahin et al., 1995; Boon and van der Bruggen, 1996; Suresh, 1996) . Brain tumours, located in an immunologically privileged site, were believed for a long time not to be involved in such immune reactions. Today, astrocytes and microglia are considered to function as antigen presenting cells (Shrikant and Benveniste, 1996) . However, with astrocytes as the essential part of the blood brain barrier, the blood brain barrier is most likely aected in astrocytic tumours. Antigens can have contact with immune competent cells and induce immune responses (Weller et al., 1992; Zinkernagel et al., 1997) .
Applying a combined immunological and molecular approach based on the antibody response against tumour-expressed antigens, we have isolated PHF3, a transcription factor-like gene in GBM whose expressed protein was detected by autologous antibodies. Here we report the relevance of PHF3, which is immunogenic in over 60% of GBM patients but not in 14 healthy control persons. The signi®cant prolonged survival of GBM patients with antibodies against PHF3 compared to the survival of PHF3-antibody negative patients supports the hypothesis that PHF3 plays an important role in GBM pathology.
GBM WHO grade IV. The autologous serum screening revealed a 2.632 kb clone with 100% identity to the 5' end of KIAA0244 (homology comprises bases 1 to 1662 of KIAA0244), a sequence that encodes a protein with unknown function. The complete open reading frame of KIAA0244 and the 2.632 kb clone encodes a predicted protein of 2039 amino acids with a calculated molecular weight of 229.45 kDa (ExPASy Compute pI/ Mw tool) and was named PHF3 (PHD finger 3), GenBank Accession Number AF091622.
Allogenic serum screening on PHF3 antigen
The allogenic GBM patient serum screening was performed to con®rm the speci®city and relevance of the antibody response to PHF3. We plated the E. coli cells transfected with the 1.884 kb PHF3 clone and GBM cDNA library containing cells separately on an agar plate. After induction of expression, plaques were transferred to nitrocellulose membranes, probed with GBM sera and then scored positive by visual inspection and in comparison to the cDNA library plaques (see Figure 1a ). An antibody-antigen reaction was detected in 24 of 39 (61.53%) GBM sera (see Table 1 ). To further evaluate the speci®city of the antibody reaction observed with GBM sera, we applied sera from healthy persons without a cancer history. None of the 14 control sera contained antibodies against PHF3. We also tested sera from patients with other glial tumours. Two of the nine sera reacted with antibody-antigen complexes (22.2%). In detail, for the group of diuse gliomas, we detected antibodies in two of three patients with WHO grade II astrocytomas (66.6%), and none in either of the two patients with WHO grade III astrocytomas. The serum deriving from a patient with an oligodendroglioma did not react with PHF3 either. Furthermore, no PHF3-speci®c antibodies were detected in any of the patients with a pilocytic astrocytoma (®ve cases). We also studied sera from patients with a meningioma as another example of intracranial tumours. PHF3-speci®c antibody reactions were detected in one of ®ve cases (20%). For testing tumours derived from another embryonic origin, we screened three sera of patients with squamous cell lung carcinomas and found no PHF3-speci®c antibody reactions in any of the sera (see Table  2 ).
Immunoblot with patients' sera
The results of the GBM patients' sera screening were con®rmed in an immunoblotting approach using a recombinantly expressed PHF3 fragment of 70 kDa, named PHF3-70. Expression of the PHF3-70 protein was con®rmed in a Western blot with the autologous GBM patient serum and could also be demonstrated by Coomassie blue staining (data not shown).
To verify the SEREX data, the recombinantly expressed PHF3 protein was now probed with the allogenic patients' sera. As a negative control, we used lysates of E. coli cultures transformed with the nonrecombinant pBK CMV vector (see Figure 1b) . We tested 15 of the 24 sera that gave positive results in the SEREX approach. Nine sera detected a 70 kDa protein in the pBK CMV/PHF3 lane but not in the negative control pBK CMV lane. 
Generation of antibodies
A peptide sequence of PHF3 was chosen to generate polyclonal antibodies in rabbits. The antibody is called PHF3-K340-antibody. The puri®ed antibody was tested for speci®city on human tissue lysates. Muscle, placenta and stomach lysates were applied to a Western blot, and the polyclonal antibody detected a 229 kDa protein corresponding to the calculated molecular weight of PHF3. In muscle, the antibody detected also several smaller products (see Figure 2a) . In addition, the speci®city of the K340 antibody was tested on the recombinantly expressed PHF3 protein.
The antibody detected a 70 kDa protein that corresponds to the molecular weight of the recombinant PHF3-70 protein (see Figure 2b) . The speci®city of the PHF3 K340 antibody was also tested by incubating the puri®ed rabbit serum with the corresponding peptide for the purpose of blocking the speci®c binding of the polyclonal antibodies. The 70 kDa signal in the immunoblot disappeared in this blocking experiment (see Figure 2b) . Thus, we conclude that the antibody is speci®c for PHF3.
Immunohistochemistry
The antibody directed against PHF3 is suitable for detection of PHF3 in formalin-®xed, paran-embedded tissue sections. It demonstrated a dierentiated immunohistochemical signal usually, though not exclusively, in the nucleus. In various non-tumourous normal tissues like muscle, for example, the antibody reveals strong nuclear staining (data not shown). Tissue sections of peripheral nervous tissue did not show reactivity. Normal brain gave only a very weak signal. In GBM, some nuclei of tumour cells surrounding necroses showed a strong staining ( Figure  3 ). The control preimmune-rabbit serum did not reveal nuclear staining of the tissue sections. To attribute the PHF3-signal to cells of astrocytic origin, we performed a double staining with PHF3-K340 antibody and GFAP-antibody which showed a co-localization ( Figure 3 ).
Prognostic value of PHF3 immune response
To evaluate the role of the PHF3 antibody response for the GBM patients as a prognostic factor, we compared the survival of 13 patients without PHF3 antibodies (PHF3AbNeg) to the survival of 18 patients who had antibodies against PHF3 (PHF3AbPos). The group of PHF3AbPos patients showed a signi®cant longer survival than the PHF3AbNeg group. Median survival in the PHF3AbPos group was 12.29 months from the date of surgery, while the median survival in the PHF3AbNeg group was 7.36 months (Log rank test: P=0.010, which is signi®cant after Bonferroni adjustment for multiplicity of four test). The relative risk associated with PHF3AbPos was 0.36 compared to PHF3AbNeg (95%-con®dence interval 0.16 ± 0.80). Entering sex or age into the model did not change the results. 
Patients' sera are termed H . . . ; +: positive reaction; 7: negative reaction 
Discussion
The immune response can be utilized as a tool to identify tumour-related genes. The physiological reaction of the immune system against tumour antigens could lead us to a new understanding of neoplasm pathogenesis. Known GBM related antigens are, for example, BAGE, GAGE, p53, bcr ± abl, Melan-A and Tyrosinase (Dietrich et al., 1997; Scarcella et al., 1999) . Some antigens are expressed only in a few tissues and tumours, like MAGE1 or GAGE1, which are expressed only in testes and in GBM and melanoma cells (Van den Bruggen et al., 1991) . For most of the known antigens, a correlation between gene mutation and immunogenicity could not be shown (Schlichtholz et al., 1992) . In addition, not all tumour-related antigens are immunogenic or trigger an eective immune response in tumour patients (Rainov et al., 1995; Gilboa, 1999) . It has been discussed that the amount of antigen is very important for the immune response (Zinkernagel et al., 1997) . Especially in GBM, the distinct heterogeneity of the tumour cells (Jung et al., 1999) entails an amount of antigen that may not be sucient for an ecient immune response. Although up to 45% of glioma patients show cytotoxic antibodies against their tumours (Kornblith et al., 1983) , this immune response usually can not be associated with a single antigen. The search for GBM relevant and not accidentally expressed antigens is rendered more dicult under these conditions. Bearing in mind these assumptions, it is important to focus the search for GBM-related antigens on those antigens that have induced an antibody response in the patient. We used a combined immunological and molecular approach known as the SEREX method to detect GBM-related antigens (Sahin et al., 1995; Tureci et al., 1997; Hampton et al., 2000) . PHF3 was identi®ed from a GBM cDNA library using autologous patient serum in the immunological screening. PHF3 is composed of a 2.632 kb clone isolated in the SEREX approach and shares 100% identity with 1662 bp at the 5' end of KIAA0244, a sequence encoding a protein with unknown function. The complete open reading frame of PHF3 encodes a predicted protein of 2039 amino acids with a calculated molecular weight of 229.45 kDa. As patients' tumour antigens can be either tumour-speci®c or patient-speci®c (Gilboa, 1999) , we tested the relevance of the PHF3 immunoreaction using sera from a group of GBM patients. Antibodies to PHF3 were detected in 24 of 39 (61.53%) of the GBM patients' sera, whereas none of the control sera reacted positively with PHF3 (see Table 1 ). This is the highest rate of speci®c reactivity that has ever been reported using a serological screening approach, considering that we have to distinguish between two types of serological immune responses. One type represents a strong antibody response in tumour patients but is not speci®c because also healthy control persons have antibodies as well. A very high rate of such an immune reaction was found, for example, against topoisomerase IIb in patients with malignant mesothelioma. Antibodies were found in 93% of the patient's sera (14 tested cases) but also in 37% of the 16 tested normal persons (Robinson et al., 2000) . The second type of antibody response represents speci®c tumour patient related antibody responses. Results for such an allogenic antibody response are reported in up to 40% (Sahin et al., 1995; Scanlan et al., 1999; GuÈ re et al., 2000) . The GBM patients' sera screening was con®rmed by Western blot analysis using recombinantly expressed PHF3-70. Nine of 15 sera were con®rmed to contain PHF3-speci®c antibodies. The remaining six negative sera may be caused by the decreased antibody titer in the sera after repeated usage in the immunological screening experiments. Furthermore, we could show that the antibody response against PHF3 was not only present in GBM patients but also detectable in other tumour patients' sera. We tested sera from patients with other glial tumours. For diuse gliomas, we detected antibodies in two of three patients with WHO grade II astrocytomas but not in patients with grade III astrocytomas or grade II oligodendrogliomas. It is evident that PHF3 antibodies can arise in a tumour stage of lower grade of malignancy than WHO grade IV. To have a more complete picture of PHF3 antibody response in glioma patients, however, more of these diuse gliomas must be studied. Sera from patients with WHO grade I pilocytic astrocytomas did not react with PHF3. Furthermore, patients with other intracranial neoplasms can generate an immune response as demonstrated in one of the ®ve tested patients with a meningioma. Sera of patients with squamous cell lung carcinomas did not react (see Table 2 ). These ®ndings imply that PHF3 may be also an interesting candidate antigen for some other kinds of neoplasms, even if the rate of antibody response found in other tumour patients was not as high as in GBM patients. In our studies, we concentrated on GBM patients, while further investigations will include also other tumour patients.
Domains of the PHF3 protein predict that PHF3 may likely function as a transcription factor, as there is a TFIIS-homology, a PHD ®nger, a proline rich region and two bipartite nuclear localization signals (see Figure 4) . PHD ®nger or LAP domains are zinc ®nger like structures (Aasland et al., 1995) . Recently described genes with PHD ®nger or LAP domain are supposed to regulate transcriptional activation. Some of them are associated with human pathological processes. PHF1 is a human cDNA with high homology to the Drosophila polycomblike gene reported to be involved in epigenetic regulations of developmental genes (Coulson et al., 1998) . PHF2 is widely expressed in human tissues and shows nuclear localization signals like PHF3. It is upregulated upon RAS transformation of 208 F-cells (Hasenpusch-Theil et al., 1999; Zuber et al., 2000) . Mutations in the PHD ®nger domain of ATRX have been discussed as the cause of the Alpha-Thalassemia/mental retardation syndrome . Loss of the PHD ®nger domain by translocation in MLLT6, AF10 and MLL in leukemia patients was reported to be critical for myoproliferation (Saha et al., 1995) .
As no mutation was found in the phf3 cDNA in GBM, and as the function of its protein remains unknown as of yet, we generated a polyclonal antibody against PHF3 to investigate its localization in normal cells and GBM. The antibody for PHF3 that speci®cally stains even formalin-®xed, paran embedded tissue sections, provides various possibilities for future experiments including Western blot experiments on human tissue lysates and additional immunohistochemistry experiments. We demonstrated the staining of a 229 kDa protein with the antibody on tissue lysates in Western blot analysis. The antibody also detects several smaller products in muscle that may correspond to degradation products of PHF3. In a ®rst histopathological study, we demonstrated nuclear expression in normal human tissue sections including normal brain, supporting the nuclear localization sites within the amino acid sequence of PHF3. The expression in GBM is speci®cally concentrated in only a few cells especially surrounding necrotic areas, where the strong reaction in these few cells is limited almost exclusively to the nuclei. We determined the PHF3-positive cells in a double staining experiment with GFAP-antibody to be of astrocytic origin. Future experiments will include a larger series of tissue sections and the SEREX-tested patients with the intention of correlating the results. GBM tissue lysates will be investigated using the PHF3-speci®c antibody to detect potential molecular weight dierences as a consequence of post-translational modi®cation.
To learn more about the role the PHF3 antibody response plays in the GBM patient, we compared the survival of antibody-positive patients with the survival of antibody-negative patients. It is known that detection of antinuclear antibodies in non-small cell lung cancer correlates with longer survival (Blaes et al., 2000) and that p53 antibodies in tumours of the breast, colon and stomach are correlated with poor prognosis (Soussi, 2000) . Obviously, there is an in¯uence of the antibody response on the tumour development in these cases. Kornblith et al. (1983) described the connection between autologous cytotoxic antibodies and a better prognosis in glioma patients. So far no individual candidate antigen is known to cause a favourable immune response in GBM. Our statistical results show a signi®cant correlation between a PHF3-speci®c antibody response and prolonged survival, as the median survival was 4.93 months longer in the PHF3 antibody positive group. The fact that a PHF3-speci®c antibody response predicts a better prognosis in GBM patients underlines the relevance of PHF3 in GBM pathology.
Materials and methods

Patients
Thirty-nine patients underwent surgical resection for a GBM between March 1996 and May 1998 in the Department of Neurosurgery, University of Saarland.
Tumour tissue and sera
The tumour tissues and sera were used with consent by the patients. Tissue samples were frozen in liquid nitrogen immediately after surgery and then stored at 7708C. The sera were prepared from 10 ml blood samples in EDTA Monovettes and stored at 7708C.
Preabsorption of sera
The serum samples were diluted 1 : 10 in 16TBS, 0.5% (wt/ vol) low-fat milk powder and 0.01% thimerosal. Two kinds of preabsorption columns were prepared with bacterial or viral antigens: The mechanical preabsorption column was incubated overnight with sonicated E. coli (Escherichia coli) XL1 blue MRF' cells in 16TBS with anity absorbent. The lytic preabsorption columns were prepared the same way but using bacteria lysed by non-recombinant ZAP express phages. The sera were preabsorbed ®ve times with each column type. After this procedure, the sera were diluted in 16TBS, 0.5% (wt/vol) low-fat milk powder and 0.01% thimerosal to a ®nal concentration of 1 : 100.
Serological screening E. coli XL1 blue MRF' cells were transfected with recombinant bacteriophage containing either the PHF3 2.623 kb cDNA or the GBM cDNA bank and plated onto NZCYM-tetracycline-agar plates. After incubation at 428C for approximately 4.5 h, ®lters pre-treated with isopropyl-b-D-thiogalactopyranoside (IPTG) were layered on the bacteriophage plaques to induce protein expression. After a second incubation of approximately 4 h at 378C, the plates were stored at 48C overnight. The ®lters containing the protein plaques were then removed and washed twice with TBS/ 0.05% Tween 20. After blocking with 5% (wt/vol) low-fat milk, ®lters were incubated with one of the prepared sera for 4 h. Antigen-antibody complexes were detected with a secondary antibody (goat antibody conjugated with alkaline phosphatase) diluted in 16TBS, 0.05% (wt/vol) low-fat milk powder. After washing the ®lters three times in 16TBS, serum-positive clones were visualized by the addition of 5-bromo-4-chloro-3-indyol-phosphate-p-toluidine salt (BCIP) and nitroblue tetrazolium-chloride (NBT) resulting in a blue staining (Heckel et al., 1997) .
PCR and cloning of phf3-70 A 1.884 kb fragment from the 5' end of PHF3 (comprising bases 753 to 2637) was generated by PCR and termed PHF3-70. Primers were synthesized with an RNA/DNA synthesizer (Applied Biosystems). Primer sequences were: phf3 Sal for: AGA GAG AGA GAG TCG ACT CCG GGA GAA ATA GAT GTG C; phf3 Not rev: GAG AGA GAG AGC GGC CGC CTA TTC TGA GGA TCT CCG AGG. PCR Conditions were: 8 h 948C, (1 h 948C, 5 h 548C, 1 h 30 min 728C)62, (1 h 948C, 1 h 588C, 1 h 30 min 728C)625, 10 h 728C, ? 158C. The PCR fragment was separated in a 1% gel by electrophoresis and isolated using the Quick Gel Extraction Kit (QIAgen). Following SalI/NotI digestion at 48C overnight, the DNA was ligated into the pBK CMV expression vector and transformed in E. Coli XL1/MRF' cells.
Expression analysis
phf3-70/pBK CMV transformed E. coli XL1/MRF' cells were grown in LB medium with kanamycin (50 mg/ml). Control cultures contained non-recombinant pBK CMV vector transformed cells. Protein expression was induced at an OD of 0.6 at 600 nm with IPTG in a ®nal concentration of 1 mM. Samples of the bacterial cultures were obtained before induction and 1, 2, 3, 4, 5 and 16 h after induction of protein expression by IPTG. Samples were spun, and the cells were diluted in SDS buer and sonicated. Bacterial protein lysates were separated by polyacrylamide gel electrophoresis in a 7.5% polyacrylamide gel and blotted to a PVDFmembrane under the conditions of 500 mA for 1.5 h. The short PHF3 protein of 70 kDa was detected with autologous patient serum. Alternatively, the polyacrylamide gel was stained with coomassie blue for 1 h and then treated with 10% methanol/10% acetic acid solution overnight.
Peptide synthesis
A peptide consisting of amino acids 831 to 845 (KRES-GEGRNSSDCRD) from the PHF3 protein was synthesized and called PHF3-K340. Peptide synthesis was performed using the Fmoc method of solid phase peptide chemistry (Merri®eld, 1963) on a Milligen/Biosearch 9050 Pep-Synthesizer. Cleavage of the peptides from the resin and removal of the protecting groups were achieved by treating the peptide with 90% tri¯uoroacetic acid, 2.5% phenol, 2.5% 1,2-ethanedithiol, 1% triisopropylsilane and 5% water.
Generation and purification of polyclonal antibodies
Antibodies were generated against the peptide plus an additional amino-terminal cysteine. The peptide was coupled to keyhole limpet haemocyanine that had been activated with N-succinimidyl-3-maleinimido-proprionate. To obtain antibodies, rabbits (bastards) were immunized by subcutaneous injections of 300 mg of coupled peptide emulsi®ed in Freund's complete adjuvant (Harlow and Lane, 1998) . The immunization was repeated twice at 2-week intervals with the same amount of coupled peptide in Freund's incomplete adjuvant. The rabbits were bled 8 ± 10 days after immunizations, and the sera were tested after each bleed on tissue lysates in Western blot analyses.
To enrich the sera for peptide-speci®c antibodies, the pretested rabbit serum was anity puri®ed using HiTrap NHSactivated anity columns from Amersham Pharmacia Biotech according to the manufacturer's instructions and the laboratory manual of Harlow and Lane (1998) . In brief, 6 mg of the PHF3-K340 peptide were coupled to the NHSactivated Sepharose column. Six millilitres of the rabbit serum were diluted 1 : 10 with 10 mM Tris, pH 7.5 and the diluted serum was applied twice to the equilibrated column. Antibodies were eluted with 100 mM glycine, pH 2.5. Fractions were immediately neutralized with 1 M Tris, pH 8.0. The ®nal concentration of the puri®ed serum was 1 : 1.83.
Western blot analysis of tissue lysates and blocking experiment
Tumour tissue was homogenized in SDS buer and sonicated. Samples were stored at 7708C. Western blot tissue lysates were diluted 1 : 10 with loading buer and separated by electrophoresis through a 7.5% polyacrylamide gel. The gel was blotted to a PVDF membrane at 330 mA for 3 h. After blocking of unspeci®c binding sites for 30 min in 16PBS, 5% (wt/vol) low-fat milk powder, the membrane was incubated with puri®ed rabbit antibody diluted in 16PBS, 0.5% (wt/vol) low-fat milk powder. Dilution factor of the puri®ed antibody was 1 : 1000. Antigen-antibodycomplexes were detected with a secondary antibody (goat anti-rabbit horseradish peroxidase conjugate) diluted 1 : 2500 in 16PBS and 0.5% (wt/vol) low-fat milk powder. The speci®c signals were visualized by a chemiluminescent reaction.
For the blocking experiment, the PHF3 K340 serum was incubated with the K340 peptide at a ®nal concentration of 200 ng/ml in 16PBS, 0.5% (wt/vol) low-fat milk powder and then applied to the Western blot with recombinantly expressed PHF3-70 as described above.
Immunohistochemistry
Immunohistochemical staining was performed on formalin®xed, paran-embedded tissue sections using the avidinbiotin peroxidase method. Pre-treatment was performed with microwave and citrate buer for 5 min at 700 W and 5 min at 350 W. The PHF3 K340 antibody was used at a dilution of 1 : 150. Incubations were for 45 min at 378C. Negative controls were performed by incubating tissue sections with antibody diluent as a substitution for the primary antibody (DAKO) or with serum from the rabbit taken before K340-immunization at a dilution of 1 : 150. The speci®c reaction of the PHF3 antibody was detected with a biotin labelled swine anti-rabbit secondary antibody. Sections where counterstained with haematoxylin after the DAB reaction.
Double labelling was performed with a monoclonal horseradish peroxidase coupled anti-human glial ®brillary acidic protein (GFAP) antibody (DAKO EPOS, DAKO, Loestrup). After detection of PHF3 as described above, the GFAP antibody was incubated for 20 min at 378C, followed by incubation with streptavidin alkaline phosphatase conjugate (Boehringer ± Mannheim) at a dilution of 1 : 50 in Trisbuer for 15 min at 378C which was detected with new fuchsin.
Statistics
Survival times of study patients were calculated from the date of surgery and estimated by the product limit method of Kaplan and Meier. Statistical evaluation was done by the log-rank test. In order to investigate the autoantibodies being an independent prognostic factor, Cox regression analysis was used. A P value of less than 0.05 was considered to be signi®cant. The p-value reported is two-sided.
